- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05766891
Opioïde-sparende effecten van door verpleegsters geleverde hypnose tijdens borstkankeroperaties
To hypnosedation alone given before and during surgery on reducing opioid use after surgery compared to standard general anesthesia given alone or with hypnosedation.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
OBJECTIVES
The proposed trial will randomize women and men with stage 0/I breast cancer scheduled for a lumpectomy, including excisional biopsy, ± sentinel node biopsy to one of three groups: 1) surgery with a local anesthetic, fentanyl, and HS before and during surgery (HS); 2) HS before surgery with usual care general anesthesia (HS-GA; total intravenous anesthesia rendering the patient unconscious with propofol infusion, airway instrumentation with a laryngeal mask airway or endotracheal tube, fentanyl, and local anesthetic); or 3) Usual care general anesthesia same as HS-GA group (GA). This project will allow further exploration of HS during surgery and to explore the biopsychosocial processes associated with analgesia and opioid use, anesthesia, and pain. We will test the hypotheses that HS during breast cancer surgery leads to reduced analgesia and opioid use, less pain and psychological stress, and faster recovery, as well as being more cost effective than GA or HS before surgery with GA.
Primary Objective:
To determine the efficacy of HS provided by a nurse anesthetist before and during surgery versus HS-GA or GA on reducing morphine equivalent daily dose (MEDD) from day of surgery through post-operative day (POD) 14.
Secondary Objectives:
- To determine the efficacy of HS with local anesthesia vs HS-GA or GA on reducing self-reported and objective pain, anxiety, nausea/vomiting, fatigue, and cognitive dysfunction.
- To evaluate group differences in costs. Using time and motion studies and methods of economic evaluation, we will test the hypothesis that HS before and during surgery will lead to less time spent in the OR and PACU, lower medication use, and less need for clinical staff engagement, leading to lower overall day of surgery-related costs.
- To explore psychosocial factors as moderators of the effects of the intervention and predictors of recovery. Baseline psychosocial factors including absorption, state and trait anxiety, intrusive thoughts, and discomfort intolerance, pain sensitivity, and expectations will moderate the effects of HS and predict outcomes over time.
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
- Fase 3
Contacten en locaties
Studiecontact
- Naam: Lorenzo Cohen, MD
- Telefoonnummer: (713) 745-4260
- E-mail: lcohen@mdanderson.org
Studie Locaties
-
-
Texas
-
Houston, Texas, Verenigde Staten, 77030
- Werving
- M D Anderson Cancer Center
-
Hoofdonderzoeker:
- Lorenzo Cohen, MD
-
Contact:
- Lorenzo Cohen, MD
- Telefoonnummer: 713-745-4260
- E-mail: lcohen@mdanderson.org
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Men and Women;
- Age 18 or older;
- Scheduled for a unilateral, breast surgical procedure, ± SLND
- Able to read, write and speak English or Spanish
- Able to sign a written informed consent and be willing to follow protocol requirements
Exclusion Criteria:
- Extreme mobility issues that preclude participating in the study
- Major thought disorders such as schizophrenia or uncontrolled bipolar disorder or PTSD
- History of chronic opioid use
- Current pain 2 or above on 0-10 scale
- Co-mobilities such as uncontrollable diabetes or hypertension
- Plastic surgery involvement for oncoplastic reconstruction
- Surgery is likely greater than 3 hours
- Patients with hearing loss that could preclude HS facilitation
- Known allergy to propofol or other medications used during surgery
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ondersteunende zorg
- Toewijzing: Gerandomiseerd
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Group 1
Participants will receive hypnosedation before and during surgery as well as local anesthesia and pain/nausea medications during surgery |
Participants will receive hypnosedation will be restarted after arriving in the operating room and will continue for the whole time of surgery |
|
Experimenteel: Group 2
Participants will receive hypnosedation before surgery and standard general anesthesia during surgery. |
Participants will receive standard general anesthesia and medications to control your pain after arriving in the operating room |
|
Experimenteel: Group 3
Participants will receive standard general anesthesia alone. You will not receive hypnosedation. |
Participants will receive standard general anesthesia and medications during surgery to control your pain. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Morphine Equivalent Daily Dose (MEDD)
Tijdsspanne: through study completion; an average of 1 year.
|
To determine the efficacy of HS provided by a nurse anesthetist before and during surgery versus HS-GA or GA on reducing morphine equivalent daily dose (MEDD) from day of surgery through post-operative day (POD) 14. |
through study completion; an average of 1 year.
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Lorenzo Cohen, MD, M.D. Anderson Cancer Center
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 2022-0959
- NCI-2023-02059 (Andere identificatie: NCI-CTRP Clinical Trials Registry)
- 5R01CA272565 (Subsidie/contract van de Amerikaanse NIH)
- CCR-23-500 (Ander subsidie-/financieringsnummer: Rising Tide Foundation for Clinical Cancer Research)
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .